Skip to main content
. 2011 Feb 18;32(6):1617–1624. doi: 10.1007/s00296-011-1807-0

Table 2.

Incidence of adverse events

Adverse event, n (%) Pre-IFX patients (n = 908) Non-IFX patients (n = 6,191) Total (n = 7,099) P value
Any adverse event 265 (29.2) 2,159 (34.9) 2,424 (34.1) <0.001
Serious adverse events 42 (4.6) 500 (8.1) 542 (7.6) <0.001
Death 2 (0.2) 31 (0.5) 33 (0.5) ns
Malignancy 1 (0.1) 17 (0.3) 18 (0.3) ns
Serious infection 23 (2.5) 202 (3.3) 225 (3.2) ns
Non-serious infection 55 (6.1)) 473 (7.6) 528 (7.4) ns

IFX infliximab; ns not significant